The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

Mylan on Tuesday earned Food and Drug Administration approval for its generic version of Teva’s multiple sclerosis drug Copaxone. 1. Mylan’s glatiramer acetate injection is intended to treat patients ...

When the tide goes out you discover who's been swimming naked. The situation is currently getting more complicated for Teva since it has lost 3 out of 5 patents. Teva is not only Copaxone franchise ...

In denying the eighth citizen petition filed by Teva Pharmaceutical Industries Ltd. to protect its blockbuster multiple sclerosis (MS) drug Copaxone from generic competition, the FDA followed a hard ...

(Reuters) - Teva Pharmaceutical Industries Ltd said on Tuesday it is "completely confident" the new version of its flagship multiple sclerosis drug, Copaxone, which features less frequent dosing, will ...